ONCR Stock Overview
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Oncorus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.13 |
| 52 Week High | US$0.47 |
| 52 Week Low | US$0.01 |
| Beta | 1.95 |
| 1 Month Change | 500.00% |
| 3 Month Change | 427.20% |
| 1 Year Change | -58.00% |
| 3 Year Change | -99.63% |
| 5 Year Change | n/a |
| Change since IPO | -99.21% |
Recent News & Updates
Recent updates
Oncorus GAAP EPS of -$0.74 misses by $0.02
Aug 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Oct 14
Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic
Jul 09Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans
May 05What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?
Feb 26Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels
Feb 02Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.
Jan 04We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate
Jan 04Oncorus reports Q3 results
Nov 11Shareholder Returns
| ONCR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 26.0% | 1.5% | 1.2% |
| 1Y | -58.0% | 1.1% | 24.7% |
Return vs Industry: ONCR underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ONCR underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| ONCR volatility | |
|---|---|
| ONCR Average Weekly Movement | 210.0% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ONCR's share price has been volatile over the past 3 months.
Volatility Over Time: ONCR's weekly volatility has increased from 101% to 210% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 64 | Craig Jalbert | www.oncorus.com |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.
Oncorus, Inc. Fundamentals Summary
| ONCR fundamental statistics | |
|---|---|
| Market cap | US$3.29m |
| Earnings (TTM) | -US$90.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ONCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$90.54m |
| Earnings | -US$90.54m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 66.0% |
How did ONCR perform over the long term?
See historical performance and comparison